Sonia B.
- Country
- Italy
- Department
- U.O. Oncologia Medica
Research Overview
- Phase 3 Evaluation of Fianlimab and Cemiplimab Versus Pembrolizumab in Treatment-Naïve Unresectable Locally Advanced or Metastatic Melanoma
- Evaluation of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab in Advanced Melanoma: A Randomized, Double-Blind, Phase 2/3 Study
- A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma
Data & Insights
Has run more than one trial at 77 of 197 partner sites.
Specializations
Prostate cancer and androgen receptor-targeted therapy
Clinical research activity is strongly centered on advanced prostate cancer, including metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and high-risk hormone-sensitive disease. The therapeutic landscape includes PARP inhibitor-based strategies, androgen deprivation therapy, and sequencing approaches in patients with progressive or biomarker-defined disease.
- Metastatic castration-resistant prostate cancer
- Metastatic castration-sensitive prostate cancer
- Homologous recombination repair-altered disease
- Androgen receptor pathway inhibition
Her work also extends to symptomatic bone-only metastatic disease, biochemical recurrence, and treatment strategies for patients with limited prior exposure to novel hormonal agents.
Breast cancer and endocrine-based treatment
Another major area of interest is breast cancer, with emphasis on triple negative breast cancer, HER2-negative disease, HER2-low breast cancer, and hormone receptor-positive early and metastatic settings. The therapeutic focus includes immunotherapy, endocrine therapy, and antibody-drug conjugate approaches.
- Triple negative breast cancer
- HER2-low and HER2-positive breast cancer
- Early breast cancer
- Metastatic breast cancer
Her portfolio also includes recurrence prevention, adjuvant treatment strategies, and management of residual disease after curative-intent therapy.
Genitourinary and gynecologic oncology
Her clinical research extends to other solid tumors, particularly urothelial cancer, renal cell carcinoma, ovarian cancer, and endometrial cancer. These studies reflect interest in disease control, maintenance treatment, and post-surgical relapse prevention across advanced oncologic settings.
- Urothelial cancer
- Metastatic renal cell carcinoma
- Recurrent ovarian cancer
- Advanced endometrial cancer
This therapeutic scope also includes biomarker-informed approaches and strategies for patients with recurrent or locally advanced disease.
Thoracic and colorectal cancer
Her trial activity includes non-small cell lung cancer, small cell lung cancer, and metastatic colorectal cancer, with attention to both first-line treatment and later-line sequencing. The research landscape also covers resected colon cancer and biomarker-driven treatment adaptation.
- Non-small cell lung cancer
- Extensive-stage small cell lung cancer
- Metastatic colorectal cancer
- Stage III colon cancer
Her involvement reflects interest in immunotherapy, targeted therapy, and circulating tumor DNA-guided management in thoracic and gastrointestinal malignancies.
Non-oncologic therapeutic areas
Beyond oncology, her clinical interests include acute myocardial infarction, eosinophilic granulomatosis with polyangiitis, rapidly progressive glomerulonephritis, chronic pelvic pain syndrome, and assisted reproductive technologies. These topics show engagement with cardiovascular, immunologic, renal, pain, and reproductive medicine.
- Acute myocardial infarction
- Eosinophilic granulomatosis with polyangiitis
- Rapidly progressive glomerulonephritis
- Chronic pelvic pain syndrome
Her research also includes colonoscopy preparation, critical illness, and supportive care-oriented interventions in non-malignant conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.